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Abst rac t
Introduction: Microbial infection and associated super antigens have been implicated in the pathogenesis of cu-
taneous T-cell lymphoma (CTCL), and many patients die from complicating bacterial infections. It has been postu-
lated that Chlamydophila pneumoniae (C. pneumoniae) infection may be involved in the pathogenesis of Mycosis 
fungoides (MF) but published data are limited and controversial.
Aim: To analyze the frequency of (C. pneumoniae) DNA presence in blood samples of lymphoma cases.
Material and methods: Using Q-PCR method we analyzed the presence of DNA in the blood samples obtained from 
57 patients with CTCL (55 – mycosis fungoides (MF)/Sézary syndrome (SS), one primary cutaneous anaplastic large 
cell lymphoma (CD30+) and one NKT cell lymphoma) and 3 patients with cutaneous B-cell lymphomas, and 120 indi-
viduals from control groups (40 patients with psoriasis, 40 patients with atopic dermatitis and 40 healthy controls). 
Results: Chlamydophila pneumoniae DNA was identified in 13 of 55 cases in the MF/SS group (23.6%), in 1 patient 
with CD30+ large cell lymphoma and in 1 of 3 patients with B-cell lymphoma. The presence of C. pneumoniae was 
confirmed in 1 of 40 psoriatic patients (2.5%), in 5 of 40 patients with atopic dermatitis (12.5%) and in none of  
40 healthy individuals. Presence of C. pneumoniae DNA in MF patients was strongly associated with disease pro-
gression; rs = 0.756; p = 0.0123 for groups IA → IVB, and was noted more frequently in advanced (III + IV) stages 
than in early (I–II) stages (p = 0.0139). There are no differences in the mean age of MF/SS patients with and without 
infection.
Conclusions: The presence of C. pneumoniae DNA in the blood cells is a frequent event in late stages of MF/SS and 
may be explained by Th2 shift and suppression of the immune system during the course of the disease.
Key words: Chlamydophila pneumoniae, late mycosis fungoides/Sézary syndrome stages, polymerase chain reaction.
Introduction
Antigen stimulation by pathogens such as bacteria 
and viruses has been considered a possible predisposing 
factor to uncontrolled cell proliferation and development 
of lymphoid and other neoplastic tissue. Helicobacter py-
lori precedes the development of gastric B-cell lymphoma, 
mycoplasma-like organisms and hepatitis C virus have 
been suggested to be associated with Hodgkin disease 
and Chlamydia trachomatis infection may associate with 
rectal and cervical cancer. Although several etiologies have 
been postulated for mycosis fungoides (MF) and Sézary 
syndrome (SS), their causes remain unknown. Based on 
the limited experimental and clinical data, it has been 
speculated that chronic local antigen stimulation by Staph-
ylococcus aureus as well as Chlamydophila pneumoniae 
(C. pneumoniae) may play a role in the pathogenesis 
of cutaneous T-cell lymphoma (CTCL) [1–3]. Chlamydo-
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phila pneumoniae is a common intracellular micro-
organism. Seroepidemiological studies indicate that 
C. pneumoniae infection is by far the most common 
human chlamydial infection in different cohorts, with 
seropositivity in at least 50% of the general popula-
tion over the age of 20 [4–10]. But polymerase chain re-
action (PCR) studies on asymptomatic healthy adults 
(more than 1000) had established only 1% of positiv-
ity in nasopharyngeal swabs’ specimens [11]. In addi-
tion to pneumonia, pharyngitis, bronchitis and asthma 
C. pneumonia is also associated with arteriosclerosis, lung 
cancer, multiple sclerosis and Alzheimer’s disease [12–18]. 
Chlamydophila pneumoniae can infect, reside and repli-
cate in various cell types including smooth muscle cells, 
fibroblasts, endothelial cells, bronchial epithelial cells, ke-
ratinocytes as well as various immune cells such as mac-
rophages, lymphocytes and natural killer cells (NK) [19, 
20]. It induces the increased release of pro-inflammatory 
mediators including tumor necrosis factor α (TNF-α), in-
terleukin 6 and 8 (IL-6, IL-8), basic fibroblast growth factor 
(bFGF) and up regulates adhesion molecules [21]. Recently 
it has been suggested that C. pneumoniae infection may 
also stimulate the IL-10 production which down regulates 
the expression of major histocompatibility complex class 
I (MHC-I), inhibits apoptosis and increases the longevity 
of the host cell, enhancing the survival of bacteria itself 
[22–24]. The role of C. pneumoniae in the etiology of CTCL 
is controversial. It has been suspected that a localized bac-
terial infection increases local production of inflammatory 
cytokines including interferon g (IFN-g) (critical in immu-
nity and immunopathology of chlamydial infection) and 
CXCL-10, a cytokine chemo attractive for epidermotropic 
T lymphocytes [24]. Studies on the growth requirements 
of the abnormal T lymphocytes in MF/SS lead to the iden-
tification of a so-called Sézary cell activation factor (SAF) 
that stimulates the growth of both malignant and non-ma-
lignant T cells. Sézary cell activation factor was original-
ly defined as an inducer of functional IL-2 receptors. It is 
postulated that a combination of SAF and IL-2 stimulates 
the propagation of oligoclonal T-cell populations from the 
peripheral blood mononuclear cells (PBMC) of patients 
with SS, with approximately one third of those cell clones 
containing the predominant malignant clone [3, 25]. Using 
a monoclonal antibody inhibitory for SAF activity Abrams 
et al. demonstrated that SAF is present in more than half 
skin biopsies taken from patients with MF [26]. It was also 
confirmed that SAF determinant is not of eukaryotic origin 
and is associated with C. pneumoniae bacteria [3]. Sézary 
cell activation factor is a protein of approximately 30 kDa, 
resembling the C. pneumoniae T cell activation factor orig-
inally described by Halme et al. [27]. Abrams et al. con-
firmed the presence of C. pneumoniae DNA and RNA in 
the skin by PCR and reverse transcription – PCR and by se-
quence analysis of the PCR products. The authors showed 
that C. pneumoniae antigen expression was associated 
with active disease and was not found after psoralen and 
ultraviolet therapy.
Material and methods 
Study and control groups
In this study 60 patients with skin lymphomas 
(48 from Poland – 30 men and 18 women, mean age: 60.7 
±13.5 and 12 from Finland – 8 men and 4 woman, mean 
age: 61.9 ±21.6) were included, of whom 57 patients were 
diagnosed with primary CTCL and 3 patients with prima-
ry cutaneous B-cell lymphomas (one follicle-center and 
two marginal zone lymphomas) according to WHO cri-
teria. The control groups consisted of 40 patients with 
psoriasis (22 men and 18 women, mean age: 49.3 ±14.3), 
40 with atopic dermatitis (21 men and 19 women, mean 
age: 13.8 ±7.7) and 40 healthy individuals (21 men, 
19 women, 10 from Finland and 30 from Poland, mean 
age: 39 ±15.0). From the 57 CTCL patients, 55 have MF or 
SS, 1 patient had primary cutaneous anaplastic large cell 
lymphoma CD (30+), and one had NK/T cell lymphoma. 
From 55 MF/SS patients, 20 were in early clinical stages 
(IA–IIA) and 35 patients were in advanced stages (IIB–
IVB). Additionally skin biopsies were obtained from 6 MF/
SS patients. 
Material collection and DNA samples 
From all patients and control groups peripheral whole 
blood samples (EDTA-K2 (Medlab Products, Raszyn, Po-
land) were collected and stored at –80°C. Additionally 
from 6 examined patients skin biopsies were collected 
and stored at –80°C. DNA was extracted using Blood Mini 
or Mini AX Tissue (A&A Biotechnology, Gdynia, Poland) 
according to the manufacturer’s protocols. Further, DNA 
was precipitated using common sodium acetate-etha-
nol technique [1] in a final volume of 20 μl and stored at 
–20°C for further analyses. DNA concentration and purity 
were assessed by NanoDrop ND1000 (ThermoScientific, 
Wilmington, DE, USA).
Chlamydophila pneumoniae strain and cell lines of 
C. pneumoniae TW183 strain was purchased from Amer-
ican Type Culture Collection (ATCC) (Rockville, MD, USA) 
and stored at –80°C. In order to propagate C. pneumo- 
niae for PCR optimization, HELA 229 line (ATCC) cells 
were infected by TW183 lysate in a 24-cell plate, followed 
by centrifugation (15 min, 400× G) and incubated at 37°C 
and 5% of CO2 for 2 days, according to ATCC protocol. Af-
ter incubation, cells were harvested and stored at –80°C. 
Presence of C. pneumoniae in cells was further confirmed 
by diagnostic nested-PCR assay (BLIRT-DNA, Gdansk, Po-
land).
Quantitative polymerase chain reaction analysis 
In order to create a specific quantitative assay for 
C. pneumoniae detection we checked (BLAST N database) 
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15 reference sequences of the C. pneumoniae strains and 
for diversification C. trachomatis strains and the ompA 
gene was chosen as a good molecular target for detec-
tion and quantification.
Optimization and validation of QPCR assay
We amplified 805 bp fragment of C. pneumoniae 
TW183 strain based on following primers: 5’CCGGCCTA-
CAATAAGCATTTAC and 5’GAGCTTCTGCAGTAAGTGACCA. 
The sequence was confirmed by RFLP method. After pu-
rification, the PCR product was cloned into pUC19 plas-
mid, followed by propagation in Escherichia coli strain, 
isolation, purification and spectrophotometric quantifica-
tion of plasmid. This construct was applied as a positive 
control for the calibration curve. The primers for QPCR 
assay were designed using VNTI software (Invitrogen, Life 
Technologies, Carlsbad, CA, USA): 5’AACAAAGTCTGCGAC-
CATCAATTAC, 5’GGCTGAGCAATGCGGATGTTATCAC. The 
conditions of PCR reaction: 2× SybrGreen Supermix (Bio-
Rad, Hercules, CA, USA), 170 nM of each primer, 4 mM 
MgCl2 and ddH2O were mixed with 2 μl of template DNA 
to a final volume of 17 μl. QPCR was performed in iCycler 
Table 1. Frequency of Chlamydophila pneumoniae DNA in blood samples from patients with various types of 
lymphomas, psoriasis, atopic dermatitis and healthy control groups
Diagnosis/clinical stage Frequency of Chlamydophila pneumoniae DNA I vs. II vs. III–IV 
stages






groups (n = 60)
MF patients:
IA 0/2 0/1 0/3 (0%) 0/16 (0%) 1/20 (5.0%)
IB 0/13 0/0 0/13 (0%)
IIA 1/3 0/1 1/4 (25%) 3/17 (17.6%)
IIB 1/11 1/2 2/13 (15%) 12/35 (34.3%)
p = 0.0139
III 3/6 0/0 3/6 (50%) 6/11 (54.5%)
IVA 0/0 1/3* 1/3 (33%)
IVB 2/2 0/0 2/2 (100%)
MF summary 9/44 (20.5%)
SS patients:
IVA 0/1 0/0 0/1
IVB 4/5 0/5 4/10 (40%)
SS summary 4/11 (36.4%)
(MF vs. SS, NS,  
p = 0.266)
All MF/SS patients 11/43 (25.6%) 2/12 (16.7%) 13/55 (23.6%)
c-ALCL (CD30+) 1/1 0 1/1
NK/T lymphoma 0/1 0 0/1
All CTCL patients 14/57 (24.5%)
Primary cutaneous B-cell 
lymphomas 
1/3 0 1/3 (33%)
All lymphomas 15/60 (25.0%)
Controls
AD patients 5/40 (12.5%)
Psoriasis patients 1/40 (2.5%)
Healthy individuals 0/40 (0%)
Positive results obtained only from skin biopsy material. MF – mycosis fungoides, SS – Sezary syndrome, c-ALCL – cutaneous anaplastic large cell lymphoma, 
AD – atopic dermatitis.
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and fluorescence data were automatically collected and 
analyzed by iCycler iQ Optical Software ver. 3.0a (Bio-
Rad, Hercules, CA, USA). QPCR conditions were: initial 
denaturation – 95°C/3 min; 40× (95°C/20 s, 65°C/30 s, 
72°C/20 s, 77°C/5 s-fluorescence reading step). A calibra-
tion curve was performed in triplicates using 6 ten-fold 
dilutions (10+8 to 10+3) of pUC19 plasmid DNA containing 
ompA gene. The slope was = –3.497; efficiency = 93.2% 
with a correlation coefficient of R2 = 0.997. Dynamic melt-
curve analysis and agarose-gel electrophoresis were used 
for all post-PCR reaction tubes to confirm the size of ex-
pected amplicon (147 bp). All reactions containing analyz-
ed DNA were performed in duplicates. If the ΔCt between 
replicates was > 0.3 and/or we found a melting peak with 
a different melting point > 1°C from the expected one, 
the reactions were repeated. As a method of quantifica-
tion we chose the relative quantity method and for histo-
graphs we applied ΔCt method, where ΔCt = (mean Ct of 
analyzed group) – (mean Ct of calibration points).
Statistical analysis
All statistical analyses were done using the Statistica 
8.0 (StatSoft Inc., Tulsa, OK, USA), Pearson and Fisher’s 
exact test. For all statistical tests, we used a comparison 
related significance level of p < 0.05.
Results
The presence of C. pneumoniae DNA was detected in 
14 of 57 (24.5%) CTCL patients and in 1 of 3 patients with 
B-cell lymphomas (primary cutaneous follicle-center B 
cell lymphoma). In the CTCL group, positive results were 
found in 13 of 55 (23.6%) MF/SS patients and in one 
patient with CD30 (+) anaplastic large cell lymphoma. 
Chlamydophila pneumonia was detected only in 1 of 
6 analyzed skin biopsies taken from MF/SS patients (Ta-
ble 1). From the controls, bacterial DNA was present in 
the blood samples in 1 of 40 (2.5%) psoriasis patients, 
in 5 of 40 (12.5%) patients with atopic dermatitis, and in 
none of 40 healthy individuals. No differences between 
MF and SS patients were observed (p = 0.266). The fre-
quency C. pneumoniae DNA in the MF/SS group corre-
lated with disease progression (rs = 0.756, p = 0.0123, 
Figure 1). None of 16 samples from MF patients with 
disease (IA or IB) were positive while C. pneumonia was 
detected in 3 of 17 (17.6%) cases in stage IIA or IIB, and 
in 6 of 11 (54.5%) MF patients in stages III or IV of dis-
ease. In SS patients, C. pneumoniae DNA was found in 
4 of 11 (36.4%) patients with stage IVB. Cumulatively in 
the MF/SS group, C. pneumoniae infection was found 
in 1 of 20 (5.0%) patients in early clinical stage (IA–IIA) 
and in 12 of 35 (34.3%) patients in advanced clinical 
stage (IIB–IVB). The results were statistically significant 
(p = 0.0139). No differences in mean age between MF/
SS patients with and without infection were observed 
(Figure 1).
Discussion
Cutaneous T-cell lymphoma is a malignancy of 
skin-homing Th1 and/or Th
2 
T cells. A prominent feature 
of CTCL is immunosuppression, which increases the risk 
of bacterial and viral infections in patients especially in 
the advanced stages of disease. The pathophysiology of 
this immunodeficiency is probably multifactorial. Data 
from experimental studies suggest that the T-cell rep-
ertoire in CTCL patients is significantly contracted [27]. 
Immunological abnormalities in CTCL are typically asso-
ciated with depressed ability of peripheral blood cells to 
produce the Th1 cytokines, IFN-g and IL-2 as a result of 
Th2 skewing [28–37]. During CTCL progression, reduced 
T-cell-mediated cellular immune responses and dimin-
ished natural killer cell activity also develop [38, 39].
Wysocka et al. have demonstrated a direct relation-
ship between the extent of the pool of circulating malig-
nant T-cells and an impaired immune response [40]. Also 
the functions of natural killer (NK) cells, including cellular 
cytotoxicity and production of IFN-g, become increasing-
ly impaired as the circulating tumor burden increases. 
The authors showed an inverse correlation between cir-
culating clonal T cells and activation status of both NK 
cells and CD8 T cells with a diminishing expression of 
a number of the activation markers CD69 and CD25, as 
well as decreased intracellular IFN-g production [40]. The 
following observations have two main pathophysiologi-
cal implications. The impaired cellular immune response, 
which is pivotal for direct antitumor responses, leads to 
further acceleration of growth of the malignant T-cells 
population. Another consequence of the decline in cy-
totoxic T-cell and NK cell functions is impaired activity 
against opportunistic infectious pathogens. This theory 
has been supported by the clinical observations [41–43]. 
It is suggested that the Th2 cytokine pattern may create 
a permissive environment for C. pneumoniae infection. 
This concept is supported by few experimental studies 
Figure 1. Frequency of Chlamydophila pneumonia in my-
cosis fungoides/Sezary syndrome patients with different 
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and clinical observations [44]. Referring to our results, 
C. pneumoniae DNA was found in 25% of all patients 
with CTCL. The frequency of chlamydial infection corre-
lated with the stage of disease. The positive results were 
seen in 5% and 34% of patients with low and high clini-
cal stages of disease, respectively. This observation may 
confirm the important role of impaired cellular immuno-
logical response in the control of opportunistic infections 
such as C. pneumoniae in CTCL patients. The association 
between Th1 response impairment and C. pneumoniae 
infection may be also supported by an increased inci-
dence of bacterial DNA in patients with atopic dermati-
tis (12.5%) (Th2 cytokines pattern) vs. psoriatic patients 
(2.5%) (Th1 cytokines pattern) and healthy controls (0%) 
(immunocompetent individuals). Chlamydophila pneu-
moniae DNA was detected only in one skin biopsy in our 
study group, in accordance with the results of German 
and Italian investigators, who did not detect any bacteri-
al DNA in skin biopsies from MF/SS patients, and confirm 
that C. pneumoniae infection could not be estimated as 
a primary triggering factor in the pathogenesis of CTCL, 
in spite of Casselli et al. who had described skin pres-
ence of Chlamydia spp. (and HHV8) in all recurrences of 
CD30+CTCL as well as in routine control blood samples 
[45–47].
Conclusions
Our results suggest that C. pneumoniae infection 
is not a primary event in the pathogenesis of CTCL, but 
may be estimated as a risk factor complicating advanced 
stages of the disease associated with Th2 shift and defi-
ciency of antibacterial defence mechanisms. 
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